Table 3.

The odds ratio estimate with 95% credible intervals of SAEs for each pair-wise comparison.

ADA+MTX	1.00 (0.64, 1.55)	1.05 (0.52, 2.16)	0.96 (0.40, 2.27)	0.42 (0.15, 1.19)	0.92 (0.36, 2.29)	1.16 (0.55, 2.32)	1.13 (0.59, 2.18)	1.11 (0.61, 2.01)
1.00 (0.64, 1.55)	cDMARDs	1.05 (0.60, 1.86)	0.95 (0.45, 2.01)	0.42 (0.16, 1.07)	0.91 (0.41, 2.05)	1.16 (0.63, 1.99)	1.12 (0.71, 1.80)	1.11 (0.73, 1.65)
0.95 (0.46, 1.93)	0.95 (0.54, 1.67)	CZP+MTX	0.90 (0.35, 2.27)	0.40 (0.13, 1.20)	0.87 (0.33, 2.32)	1.09 (0.48, 2.36)	1.06 (0.52, 2.23)	1.04 (0.52, 2.10)
1.04 (0.44, 2.48)	1.05 (0.50, 2.20)	1.11 (0.44, 2.83)	ETN+MTX	0.44 (0.13, 1.43)	0.96 (0.32, 2.83)	1.23 (0.46, 3.03)	1.19 (0.50, 2.86)	1.16 (0.49, 2.69)
2.36 (0.84, 6.82)	2.36 (0.93, 6.17)	2.51 (0.84, 7.61)	2.25 (0.70, 7.61)	GOL	2.16 (0.90, 5.64)	2.75 (0.92, 8.25)	2.66 (0.96, 7.61)	2.61 (0.94, 7.39)
1.08 (0.44, 2.75)	1.09 (0.49, 2.46)	1.15 (0.43, 3.06)	1.04 (0.35, 3.10)	0.46 (0.18, 1.12)	GOL+MTX	1.27 (0.46, 3.35)	1.21 (0.48, 3.16)	1.20 (0.49, 2.97)
0.86 (0.43, 1.80)	0.86 (0.50, 1.58)	0.91 (0.42, 2.10)	0.81 (0.33, 2.18)	0.36 (0.12, 1.08)	0.79 (0.30, 2.16)	IFX+MTX	0.96 (0.48, 2.12)	0.95 (0.49, 1.95)
0.89 (0.46, 1.68)	0.90 (0.55, 1.40)	0.94 (0.45, 1.93)	0.84 (0.35, 1.99)	0.38 (0.13, 1.04)	0.83 (0.32, 2.08)	1.04 (0.47, 2.08)	TCZ	0.98 (0.61, 1.52)
0.90 (0.50, 1.65)	0.90 (0.61, 1.36)	0.96 (0.48, 1.93)	0.86 (0.37, 2.03)	0.38 (0.14, 1.06)	0.84 (0.34, 2.03)	1.05 (0.51, 2.05)	1.02 (0.66, 1.63)	TCZ+MTX

cDMARDs, conventional disease-modifying antirheumatic drugs; MTX, methotrexate; ADA, adalimumab; CZP, certolizumab; ETN, etanercept; GOL, golimumab; IFX, infliximab; TCZ, tocilizumab; PBO, placebo.